Orion Oyj Cancer Trial Adds Potential Upside To Discounted Share Price

• Orion Oyj has started a Phase 1b/2 basket trial of ODM-212, an oral pan TEAD inhibitor.
• The study targets patients with advanced cancers, including mesothelioma, KRAS G12C mutated non small cell lung cancer, and pancreatic cancer.
• The trial initiation marks a new clinical step for Orion Oyj in oncology research.

For investors watching HLSE:ORNBV, this new trial adds a fresh clinical asset to an already established pharma business. The share price is currently €68.7, with the stock up 3.1% over the past week and 25.6% over the past year. Over a 5-year period, the share price return is 119.5%, indicating how the market has valued Orion Oyj over a longer horizon.

The move of ODM-212 into Phase 1b/2 gives Orion Oyj another potential opportunity in areas of oncology where treatment options are limited. As the trial progresses, investors can watch for updates on safety, dosing, and early signs of clinical activity, as these will influence how meaningful this program could become within the broader pipeline.

Stay updated on the most important news stories for Orion Oyj by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Orion Oyj.

We've flagged 2 risks for Orion Oyj. See which could impact your investment.

Quick Assessment

• ✅ Price vs Analyst Target: At €68.7, Orion Oyj trades about 7% below the €74.17 analyst target.
• ✅ Simply Wall St Valuation: Shares are assessed as trading 51.1% below estimated fair value.
• ❌ Recent Momentum: The 30 day return is a 4.2% decline.

There is only one way to know the right time to buy, sell or hold Orion Oyj. Head to Simply Wall St's company report for the latest analysis of Orion Oyj's fair value.

Key Considerations

• 📊 The ODM-212 trial gives Orion Oyj another oncology shot on goal, while the current €68.7 price already sits below both analyst and modelled fair value levels.
• 📊 Watch readouts from the Phase 1b/2 basket study alongside the P/E of 18.3 and any changes to the €55 to €81 target range as data rolls in.
• ⚠️ The company has high non cash earnings and the 2.62% dividend is not well covered by free cash flow, so investors may want to stress test cash generation if R&D spend rises.

Dig Deeper

For the full picture, including more risks and rewards, check out the complete Orion Oyj analysis. Alternatively, you can visit the community page for Orion Oyj to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com